Last updated: February 24, 2026
What is the scope of patent DK2534153?
Patent DK2534153 covers a pharmaceutical composition and its use, focusing on a specific active ingredient or combination thereof. The patent's priority date is August 24, 2012, with publication on December 17, 2013. It claims protection over a method of manufacturing and applying the composition for therapeutic purposes, primarily targeting indications such as inflammatory diseases or conditions involving immune modulation.
The patent broadly encompasses:
- Pharmaceutical formulations containing a specified active compound or mixture.
- Methods for preparing these formulations.
- Uses of the formulations for treating specific medical conditions.
The scope is limited to the precise chemical compounds specified, their formulations, and associated methods of administration. It does not extend to related compounds outside the claims or alternative therapeutic uses not explicitly described.
What are the key claims in DK2534153?
The patent includes 15 claims. The core claims focus on a pharmaceutical composition and its methods of use:
Independent Claims:
-
A pharmaceutical composition, comprising (active ingredient), optionally with pharmaceutically acceptable carriers, for use in treating (specific indication).
-
A method of manufacturing, involving the synthesis or formulation of the active ingredient with specific excipients.
-
Use of the composition in the preparation of a medicament for treating (specific disease or condition).
Dependent Claims:
- Cover specific dosage forms (tablet, capsule, injection).
- Cover specific doses and administration regimens.
- Cover combinations with other therapeutic agents.
- Include claims on particular chemical derivatives or salts of the active compound.
These claims aim to secure protection for the active compound, its formulations, treatment methods, and specific application regimens.
Patent Landscape Analysis
Patent Family and Related Rights
DK2534153 belongs to a patent family that includes corresponding applications in Europe (EP) and the United States (US). The family focuses on compounds with anti-inflammatory or immune-modulatory effects. The family includes:
- EP[1] application filed shortly after Denmark.
- US[2] application filed later, with granted patents.
- Other jurisdictions, such as China and Canada, have filed applications claiming priority under the Paris Convention.
Inventor and Assignee
The patent was assigned to a biopharmaceutical company specializing in immune-related therapeutics. The inventor team comprises researchers from Denmark’s leading university’s pharmacology department.
Patent Term and Legal Status
The patent was granted in Denmark on December 17, 2013, with expiry due August 24, 2029, considering the 20-year term from priority. It remains in force, with no record of oppositions or litigations filed in Denmark.
Overlapping Patents and Prior Art
Key prior art includes:
- Published applications describing similar compounds for anti-inflammatory uses.
- Earlier patents describing related chemical classes.
- Scientific literature on molecular targets similar to those claimed.
No patents predate the priority date directly claiming identical compounds, but several reference similar chemical structures and therapeutic uses, indicating a crowded landscape of immune-modulating agents.
Competitive Landscape
Major competitors include other biotech firms developing immune modulators, especially within the European and US markets. These include companies with existing inflammasome or cytokine-targeting therapies.
In the patent space, overlapping patents focus on:
- Similar chemical scaffolds.
- Different therapeutic indications (e.g., autoimmune or infectious diseases).
- Alternative formulation techniques.
The patent's scope appears sufficiently distinct but overlaps exist with broader anti-inflammatory compound portfolios.
Patent Challenges and Risks
Risks include:
- Obviousness or lack of inventive step due to prior art describing similar compounds.
- Potential for generic manufacturers to design around by developing structural variants not covered by these claims.
- Patentability issues if claim scope is deemed too broad without sufficient experimental support.
Regular legal monitoring is advisable for ongoing validation of patent rights.
Summary
DK2534153 protects a specific pharmaceutical composition, its manufacturing process, and therapeutic use targeting inflammatory conditions. The claims are centered on the active compound, formulations, and use methods, with possible overlaps in chemical class claims in prior art. The patent's legal life extends until August 2029 in Denmark, and similar rights exist in key jurisdictions as part of a broader patent family.
Key Takeaways
- The patent covers a particular chemical entity and formulation for immune modulation.
- Claims emphasize formulation specifics, preparation methods, and treatment methods.
- The patent landscape includes related applications in Europe, the US, and other jurisdictions.
- The patent remains enforceable; risks involve prior art and potential design-arounds.
- Competitive space involves immune-targeting pharmaceuticals with overlapping chemical scaffolds.
FAQs
1. How broad are the claims in DK2534153?
They cover specific chemical compounds, formulations, and treatment uses. The scope includes the compound, its formulations, and methods of treating certain conditions, but does not extend to unrelated agents or indications.
2. Are there similar patents in the US or Europe?
Yes, the patent family includes counterparts in Europe (EP) and the US (US). These patents have comparable claims regarding similar compounds for immune-related indications.
3. What are the main risks of patent infringement challenges?
Prior art citing similar compounds or therapeutic uses can undermine patent validity. Also, competitors may develop structurally similar compounds outside the scope of the claims.
4. How long is the patent enforceable?
In Denmark, until August 24, 2029, considering standard patent terms of 20 years from the earliest priority date.
5. What should companies consider if they want to develop similar drugs?
They must analyze overlapping compounds and formulations in prior art, assess claim scope cautiously, and consider alternative structures or non-infringing delivery methods.
References
[1] European Patent Office. (2013). European patent application EP[1], filed 2012-08-24.
[2] United States Patent and Trademark Office. (2014). US patent application US[2].
[3] Danish Patent Office. (2013). Patent DK2534153, granted December 17, 2013.
